DUBLIN – Nerre Therapeutics Ltd. may have missed the primary endpoint of a phase IIb trial of its lead drug, orvepitant, in chronic cough, but clinically relevant and statistically significant signals on three secondary endpoints leave it convinced that it has an active drug on its hands. The company is now seeking an end-of-phase II meeting with the FDA and EMA to determine the next steps for the program.